In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Jounce gets $261mm up front in major Celgene immuno-oncology deal; deal ends

Executive Summary

Jounce Therapeutics Inc. and Celgene Corp. teamed up to co-develop and sell Jounce's lead immuno-oncology candidate JTX2011 and up to five additional early-stage immunotherapies.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Contract
    • Intra-Biotech Deal
    • Includes Royalty or Profit Split Information
    • Includes Equity
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register